Hematologic Malignancies

UCSF

Questions discussed in this category

How would you approach therapy for a patient with smoldering multiple myeloma whose light chain ratio has increased to greater than 100 over several years in the absence of any other myeloma-defining events?

Does a progressing kappa/lambda ratio > 100 at any point in time warrant treatment, or does one wait to treat patients in the setting of a slowly i...

2 Answers available

For patients with mild CKD, how do you decide between zoledronic acid and denosumab for bone protection in patients with multiple myeloma?

For pts w/ eGFR between 30-60

1 Answer available

How do you approach patients with recurrent grade 3+ neutropenia on IMiD-containing regimens (e.g., VRd or KRd) beyond dose reductions?

For example: shorten IMiD duration each cycle, add scheduled G-CSF, add antibacterial prophylaxis, etc.

1 Answer available

What is the optimal prophylaxis regimen to use prior to a selinexor based regimen in the treatment of multiple myeloma for nausea and electrolyte abnormalities?

2 Answers available

Papers discussed in this category

Clin Lymphoma Myeloma Leuk, 2020 Mar 07

Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With Selinexor.

Clin Lymphoma Myeloma Leuk, 2021 Jul 18

Optimal Supportive Care With Selinexor Improves Outcomes in Patients With Relapsed/Refractory Multiple Myeloma.

Blood, 2011-09-15

Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease.

Haematologica, 2011 Dec 01

Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial.

Cancer Chemother Pharmacol, 2016 Jun 10

Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment.

Clin Cancer Res, 2020 Aug 17

Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation.

Lancet Oncol, 2014 Oct 26

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

Blood cancer journal, 2016-07-29

Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma.

Leukemia, 2022 Apr 11

Correction: Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100.

Hematologic Malignancies

UCSF

Questions discussed in this category

Papers discussed in this category

Related Topics in Hematologic Malignancies